Harvoni is a polymerase inhibitor used to treat patients infected with Genotype 1 and 4 of Hepatitis C. The treatment can be administered to patients coinfected with the HIV virus and suffering from liver cirrhosis. In some cases this medicine has been used successfully to treat patients that cannot be treated with therapies of interferon.
It is important to say that this treatment has been broadly proved in its efficacy and safety. The medicine has been evaluated in six different studies with almost 2,000 participants.
The components of
Harvoni generic the Sofosbuvir and Ledipasvir
fight some proteins that facilitate the reproduction of the virus thus suppressing the progression of it and giving the opportunity to the patient to heal the liver.
This treatment is expensive, but the results are excellent. Gilead the company that owns the rights of this medicine has signed agreements with local pharmaceuticals to allow them to manufacture the Harvoni Generic. Although the company has signed with Natco from India the rights to manufacture locally the generic version, the process is still waiting for approval of the local government there.
Some recent news says that the treatment will be available sometime between September and October 2015.
If you are in need of keeping posted about the release of the generic version of Harvoni contact us
